These mutations impair microglial responses to amyloid and lipid metabolism and confer a 3- to 4.5-fold increased risk of AD, comparable to the risk associated with a single copy of APOE ε4 (Guerreiro et al., 2013, Ulland et al., 2017). This evidence concerns the gene APOE and Alzheimer disease.